Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal

Sub-Saharan Africa accounts for almost 70 % of people living with HIV (PLWH) worldwide, with the greatest numbers centred in South Africa where 98 % of infections are caused by subtype C (HIV-1C). However, HIV-1 subtype B (HIV-1B), prevalent in Europe and North America, has been the focus of most cure research and testing despite making up only 12 % of HIV-1 infections globally. Development of latency models for non-subtype B viruses is a necessary step to address this disproportionate focus. Furthermore, the impact of genetic variation between viral subtypes, specifically within the long terminal repeat (LTR) element of the viral transcriptional promoter on latency reversal, remains unclear. To address this scientific gap, we constructed a minimal genome retroviral vector expressing HIV-1C consensus transactivator of transcription protein (Tat) and green fluorescent protein (GFP) under the control of either HIV-1C consensus LTR (C731CC) or the transmitted/founder (T/F) LTRs derived from PLWH (C<sub>T/F</sub>731CC), produced corresponding LTR pseudotyped viruses using a vesicular stomatitis virus (VSV-G) pseudotyped Envelope vector and the pCMVΔR8.91 packaging vector containing HIV-1 accessory and <i>rev</i> genes. Viruses produced in this way were used to infect Jurkat E6 and primary CD4<sup>+</sup> T cells <i>in vitro</i>. By enriching for latently infected cells, and treating them with different latency reversing agents, we developed an HIV-1C latency model that demonstrated that the HIV-1C consensus LTR has lower reactivation potential compared to its HIV-1B counterpart. Furthermore, HIV-1C T/F LTR pseudotyped proviral genetic variants exhibited a heterogenous reactivation response which was modulated by host cell (genetic) variation. Our data suggests that genetic variation both within and between HIV-1 subtypes influences latency reversal. Future studies should investigate the specific role of variation in host cellular environment on reactivation differences.

Authors

Institutions

Publication Details

Journal
Journal of Virus Eradication
Published
2024-12-01
DOI
https://doi.org/10.1016/j.jve.2024.100575
Citations
2
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.59

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal

Shreyal Maikoo, Robert‐Jan Palstra, Paradise Madlala, Thumbi Ndung’u et al.
2 citations
Journal of Virus Eradication
HIV Research and Treatment
0.59
article

Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal

Shreyal Maikoo, Robert‐Jan Palstra, Paradise Madlala, Thumbi Ndung’u, Tokameh Mahmoudi, Krista L. Dong
article en
2 citations

Abstract

Sub-Saharan Africa accounts for almost 70 % of people living with HIV (PLWH) worldwide, with the greatest numbers centred in South Africa where 98 % of infections are caused by subtype C (HIV-1C). However, HIV-1 subtype B (HIV-1B), prevalent in Europe and North America, has been the focus of most cure research and testing despite making up only 12 % of HIV-1 infections globally. Development of latency models for non-subtype B viruses is a necessary step to address this disproportionate focus. Furthermore, the impact of genetic variation between viral subtypes, specifically within the long terminal repeat (LTR) element of the viral transcriptional promoter on latency reversal, remains unclear. To address this scientific gap, we constructed a minimal genome retroviral vector expressing HIV-1C consensus transactivator of transcription protein (Tat) and green fluorescent protein (GFP) under the control of either HIV-1C consensus LTR (C731CC) or the transmitted/founder (T/F) LTRs derived from PLWH (C<sub>T/F</sub>731CC), produced corresponding LTR pseudotyped viruses using a vesicular stomatitis virus (VSV-G) pseudotyped Envelope vector and the pCMVΔR8.91 packaging vector containing HIV-1 accessory and <i>rev</i> genes. Viruses produced in this way were used to infect Jurkat E6 and primary CD4<sup>+</sup> T cells <i>in vitro</i>. By enriching for latently infected cells, and treating them with different latency reversing agents, we developed an HIV-1C latency model that demonstrated that the HIV-1C consensus LTR has lower reactivation potential compared to its HIV-1B counterpart. Furthermore, HIV-1C T/F LTR pseudotyped proviral genetic variants exhibited a heterogenous reactivation response which was modulated by host cell (genetic) variation. Our data suggests that genetic variation both within and between HIV-1 subtypes influences latency reversal. Future studies should investigate the specific role of variation in host cellular environment on reactivation differences.

Journal of Virus EradicationVol. 10(4)
Harvard University (US), Erasmus MC (NL), Ragon Institute of MGH, MIT and Harvard (US), Massachusetts General Hospital (US), Africa Health Research Institute (ZA), University College London (GB), University of KwaZulu-Natal (ZA)
Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, Gilead Sciences, Wellcome Trust, European Commission, National Research Foundation, South African Medical Research Council, Poliomyelitis Research Foundation, Medical Research Council, Erasmus+
Good health and well-being
Openalex Percentile: Top 31%
HIV Research and Treatment
0.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.